跳至主要内容
临床试验/CTRI/2026/01/100453
CTRI/2026/01/100453尚未招募2/3 期

A Pilot Clinical Study to Assess the Effect of Netra-Tarpana on Certain Ocular Parameters in Patients with Myopia.

Dr Varsha Raj1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2026年1月22日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
发起方
入组人数
40
试验地点
1

研究概览

简要总结

Purpose: To assess the effect of Netra-Tarpana (utilizing Mahatriphaladi ghrita) on certain ocular parameters, including best corrected visual acuity (BCVA), refractive error, prescription strength, keratometry readings, axial length, and intraocular pressure (IOP) in individuals with myopia.

Study Design: Clinical, prospective, open-labeled, single-group, single-blind, pilot study.

Participants: (n = 40) Patients of either gender, aged 10-45 years, diagnosed with myopia with spherical equivalent refractive error between -0.5 to -6.0 diopters, with stable refractive status for at least six months prior to enrollment. The diagnosis of myopia will be made on baseline day (day 0) using objective (retinoscopy, autorefractometer) and subjective refraction, and the spherical equivalent will be recorded for best corrected visual acuity.

Methods: All recruited participants (n = 40) will undergo Poorva Karma (local snehana with Tila Taila, Mridu Swedana, and Nasya with Shadbindu Taila), followed by Pradhana Karma - Netra-Tarpana with Mahatriphala Ghrita (30 ml) for three seven-day sittings at fifteen-day intervals - and Pashchat Karma with lukewarm-water Netra-Prakshalana. Standardized and certified formulations will be used. Baseline evaluation will include visual acuity, refraction, slit-lamp and fundus examination, IOP measurement, keratometry, and A-scan biometry. All parameters will be assessed before and after each sitting; changes in refractive status and ocular findings will be documented, and participant feedback will be recorded. follow-up will occur on day 0, 7, 23, 29, 45, 52.

Main Outcome Measures: The primary efficacy outcomes will include changes in visual acuity and spherical equivalent refractive error from baseline to the end of treatment. Secondary outcomes will assess changes in keratometry readings, axial length, anterior chamber depth, and intraocular pressure over the study period.

Results: The mean change in all assessment parameters will be analyzed using appropriate parametric or non-parametric statistical tests, as recommended by the statistician, to compare baseline and post-treatment values. A p-value of 0.05 or less will be considered statistically significant for all analyses.

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
10.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • Patients who meet the following criteria will be selected for the study:
  • Patients aged 10 to 45 years.
  • Patients diagnosed with myopia with spherical equivalent refractive error between minus 0.5 to minus 6.0 diopters.
  • Patients with stable refractive status for at least six months prior to enrollment.
  • Patients without any systemic disease that may affect ocular health, such as uncontrolled diabetes or autoimmune disorders.
  • Patients who are able and willing to provide written informed consent and are likely to complete the entire course of the study as per instructions.

排除标准

  • Patients will be excluded from enrollment if they have:
  • High myopia with spherical equivalent refractive error greater than minus 6.0 diopters.
  • History of ocular surgery, such as refractive or cataract surgery, within the past one year.
  • Presence of ocular pathology other than myopia, such as glaucoma, retinal detachment, or macular degeneration.
  • Female patients who are pregnant, planning pregnancy during the study period, or lactating.
  • Current use or planned use of contact lenses during the study period.
  • Severe dry eye syndrome or any ocular surface disease that may affect study outcomes.
  • Use of ocular medications such as topical steroids or anti-glaucoma drugs that may interfere with the assessment of outcomes.
  • Inability to continue the proposed duration of treatment or attend follow-up visits.
  • Current participation in another clinical trial or participation in an ocular clinical trial within the past three months.

研究者

发起方
Dr Varsha Raj
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Varsha Raj

Government Ayurvedic College and Hospital, Kadamkuan, Patna, Bihar, India.

研究点 (1)

Loading locations...

相似试验